Monte Rosa Therapeutics Statistics
Share Statistics
Monte Rosa Therapeutics has 61.44M shares outstanding. The number of shares has increased by 23.59% in one year.
| Shares Outstanding | 61.44M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.36% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 46.20M |
| Failed to Deliver (FTD) Shares | 1.26K |
| FTD / Avg. Volume | 0.05% |
Short Selling Information
The latest short interest is 7.84M, so 12.76% of the outstanding shares have been sold short.
| Short Interest | 7.84M |
| Short % of Shares Out | 12.76% |
| Short % of Float | 16.97% |
| Short Ratio (days to cover) | 1.65 |
Valuation Ratios
The PE ratio is -2.15 and the forward PE ratio is -6.09.
| PE Ratio | -2.15 |
| Forward PE | -6.09 |
| PS Ratio | 0 |
| Forward PS | 42.6 |
| PB Ratio | 1.62 |
| P/FCF Ratio | -4.62 |
| PEG Ratio | n/a |
Enterprise Valuation
Monte Rosa Therapeutics Inc. has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 5.07, with a Debt / Equity ratio of 0.02.
| Current Ratio | 5.07 |
| Quick Ratio | 5.07 |
| Debt / Equity | 0.02 |
| Total Debt / Capitalization | 1.73 |
| Cash Flow / Debt | -13.85 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.76% and return on capital (ROIC) is -63.77%.
| Return on Equity (ROE) | -0.76% |
| Return on Assets (ROA) | -0.45% |
| Return on Capital (ROIC) | -63.77% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -1.02M |
| Employee Count | 133 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 338.00K |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 50.8% in the last 52 weeks. The beta is 1.3, so Monte Rosa Therapeutics 's price volatility has been higher than the market average.
| Beta | 1.3 |
| 52-Week Price Change | 50.8% |
| 50-Day Moving Average | 7.68 |
| 200-Day Moving Average | 5.89 |
| Relative Strength Index (RSI) | 43.26 |
| Average Volume (20 Days) | 2.57M |
Income Statement
In the last 12 months, Monte Rosa Therapeutics had revenue of $0 and earned -$135.35M in profits. Earnings per share was $-2.63.
| Revenue | 0 |
| Gross Profit | -6.22M |
| Operating Income | -143.31M |
| Net Income | -135.35M |
| EBITDA | -137.09M |
| EBIT | - |
| Earnings Per Share (EPS) | -2.63 |
Balance Sheet
The company has $128.10M in cash and $46.04M in debt, giving a net cash position of $82.06M.
| Cash & Cash Equivalents | 128.10M |
| Total Debt | 46.04M |
| Net Cash | 82.06M |
| Retained Earnings | -365.89M |
| Total Assets | 315.08M |
| Working Capital | 209.57M |
Cash Flow
In the last 12 months, operating cash flow was -$43.80M and capital expenditures -$19.04M, giving a free cash flow of -$62.84M.
| Operating Cash Flow | -43.80M |
| Capital Expenditures | -19.04M |
| Free Cash Flow | -62.84M |
| FCF Per Share | -1.22 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
GLUE does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -34.88% |
| FCF Yield | -13.58% |
Analyst Forecast
The average price target for GLUE is $16, which is 112.2% higher than the current price. The consensus rating is "Buy".
| Price Target | $16 |
| Price Target Difference | 112.2% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
Scores
| Altman Z-Score | 0.13 |
| Piotroski F-Score | 3 |